Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ZX-7101A on QTc Interval in Healthy Subjects
NCT05955027Phase 1Completed
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Seloxavir marboxil in influenza (3 arms), sponsored by Zenshine Pharmaceuticals Co., Ltd. Primary endpoint: Placebo-corrected, baseline-adjusted QTc interval at Day 15. Started Jul 2023; status: completed.
02
Drugs
Seloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05955027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955027.